These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
435 related articles for article (PubMed ID: 16951141)
1. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Wang J; Cai Y; Ren C; Ittmann M Cancer Res; 2006 Sep; 66(17):8347-51. PubMed ID: 16951141 [TBL] [Abstract][Full Text] [Related]
2. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Hermans KG; Boormans JL; Gasi D; van Leenders GJ; Jenster G; Verhagen PC; Trapman J Clin Cancer Res; 2009 Oct; 15(20):6398-403. PubMed ID: 19825963 [TBL] [Abstract][Full Text] [Related]
3. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538 [TBL] [Abstract][Full Text] [Related]
4. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Winnes M; Lissbrant E; Damber JE; Stenman G Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040 [TBL] [Abstract][Full Text] [Related]
5. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer]. Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766 [TBL] [Abstract][Full Text] [Related]
6. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Demichelis F; Fall K; Perner S; Andrén O; Schmidt F; Setlur SR; Hoshida Y; Mosquera JM; Pawitan Y; Lee C; Adami HO; Mucci LA; Kantoff PW; Andersson SO; Chinnaiyan AM; Johansson JE; Rubin MA Oncogene; 2007 Jul; 26(31):4596-9. PubMed ID: 17237811 [TBL] [Abstract][Full Text] [Related]
7. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. Rostad K; Hellwinkel OJ; Haukaas SA; Halvorsen OJ; Øyan AM; Haese A; Budäus L; Albrecht H; Akslen LA; Schlomm T; Kalland KH APMIS; 2009 Aug; 117(8):575-82. PubMed ID: 19664128 [TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence. Hagen RM; Adamo P; Karamat S; Oxley J; Aning JJ; Gillatt D; Persad R; Ladomery MR; Rhodes A Am J Clin Pathol; 2014 Oct; 142(4):533-40. PubMed ID: 25239421 [TBL] [Abstract][Full Text] [Related]
12. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564 [TBL] [Abstract][Full Text] [Related]
13. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102 [TBL] [Abstract][Full Text] [Related]
14. The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma. Lucas JM; True L; Hawley S; Matsumura M; Morrissey C; Vessella R; Nelson PS J Pathol; 2008 Jun; 215(2):118-25. PubMed ID: 18338334 [TBL] [Abstract][Full Text] [Related]
15. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502 [TBL] [Abstract][Full Text] [Related]
16. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data. Rouzier C; Haudebourg J; Carpentier X; Valério L; Amiel J; Michiels JF; Pedeutour F Cancer Genet Cytogenet; 2008 May; 183(1):21-7. PubMed ID: 18474293 [TBL] [Abstract][Full Text] [Related]
17. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Leinonen KA; Tolonen TT; Bracken H; Stenman UH; Tammela TL; Saramäki OR; Visakorpi T Clin Cancer Res; 2010 May; 16(10):2845-51. PubMed ID: 20442300 [TBL] [Abstract][Full Text] [Related]
18. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models. Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461 [TBL] [Abstract][Full Text] [Related]
19. Expression of the prostate cancer metastasis suppressor gene KAI1 in primary prostate cancers: a biphasic relationship with tumour grade. Bouras T; Frauman AG J Pathol; 1999 Aug; 188(4):382-8. PubMed ID: 10440748 [TBL] [Abstract][Full Text] [Related]
20. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer. Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]